Citius Oncology gets Nasdaq extension to April 2027 on bid price rule

Citius Oncology, Inc. disclosed in an 8-K filing that on October 19, 2026, it received formal notice that the Nasdaq Stock Market LLC granted its request for an extension through April 19, 2027 to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2).¹

Under the terms of the extension, if at any time before April 19, 2027, the bid price of the company's common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the company with written confirmation of compliance with the Bid Price Rule.¹

The filing also outlines the consequences of noncompliance. If the company does not regain compliance with the Bid Price Rule by April 19, 2027, Nasdaq will provide written notice to the company that its common stock is subject to delisting, at which point the company may appeal the determination to a Nasdaq hearings panel.¹

For now, the company's stock listing is unaffected. The Extension Notice has no effect at this time on the listing of the company's common stock, which will continue to trade on The Nasdaq Capital Market under the symbol "CTOR."¹

Citius Oncology stated that it is currently evaluating its options for regaining compliance, though there can be no assurance that the company will be able to regain compliance with the Bid Price Rule, even if it maintains compliance with the other listing requirements.¹

The 8-K was signed by Leonard Mazur, Chairman and Chief Executive Officer, and dated October 23, 2026.